Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | METAP1 | P53582 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | ADH1B | P00325 | 1/20 | 0.34 |
| ▸ | ADH1C | P00326 | 1/20 | 0.34 |
| ▸ | ADH1A | P07327 | 1/20 | 0.34 |
| ▸ | ADH4 | P08319 | 1/20 | 0.34 |
| ▸ | ADH7 | P40394 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2704009 | 1.00 | CYP1A2 (0.42) | CYP1A2SIGMAR1HPGDMETAP1EPHX1 | |
| SCHEMBL96802 | 0.97 | — | — | |
| SCHEMBL5218136 | 0.92 | — | — | |
| SCHEMBL98082 | 0.86 | — | — | |
| SCHEMBL8390897 | 0.85 | CYP1A2 (0.50) | CYP1A2SIGMAR1HPGDMETAP1EPHX1 | |
| SCHEMBL99022 | 0.85 | CYP1A2 (0.50) | CYP1A2SIGMAR1HPGDMETAP1EPHX1 | |
| SCHEMBL7350448 | 0.83 | SIGMAR1 (0.50) | CYP1A2SIGMAR1EPHX1 | |
| SCHEMBL97094 | 0.83 | SIGMAR1 (0.50) | CYP1A2SIGMAR1EPHX1 | |
| SCHEMBL1335898 | 0.83 | SIGMAR1 (0.50) | CYP1A2SIGMAR1EPHX1 | |
| SCHEMBL8075929 | 0.83 | ALDH1A1 (0.32) | CYP1A2HPGDEPHX1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 497 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10787484-B2 | Compositions and methods for treating cardiovascular disease | GENENTECH, INC. (US) | 2020-09-29 | — | — | US | claimed |
| US-20190177366-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE | GENENTECH, INC. (US) | 2019-06-13 | — | — | US | claimed |
| CN-109475593-A | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE | 豪夫迈·罗氏有限公司 | 2019-03-15 | — | — | CN | claimed |
| CN-102947378-A | Clarified polypropylene articles with improved optical properties and/or increased temperature of crystallization | BASF SE | 2013-02-27 | — | — | CN | claimed |
| US-8012975-B2 | These compounds lack a 1,4-bridging group as found in the ecteinascidins; and, have at the C-1 position a substituent selected from an amino or hydroxy group, optionally protected or derivatized; anticarcinogenic agents | PHARMA MAR, S.A. (ES) | 2011-09-06 | — | — | US | claimed |
| US-7666866-B2 | Antithrombotic diamides | ELI LILLY AND COMPANY (US) | 2010-02-23 | — | — | US | claimed |
| EP-1819693-B1 | ANTITHROMBOTIC DIAMIDES | LILLY CO ELI (US) | 2009-08-26 | — | — | EP | claimed |
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | claimed |
| US-20090062271-A1 | Antithrombotic Diamides | ELI LILLY AND COMPANY (US) | 2009-03-05 | — | — | US | claimed |
| EP-1940785-A2 | ACYCLIC 1,4-DIAMINES AND USES THEREOF | SmithKline Beecham Corporation (US) | 2008-07-09 | — | — | EP | claimed |
| EP-0374098-A2 | Inhibitors of retroviral proteases | CIBA-GEIGY AG (CH) | 1990-06-20 | — | — | EP | claimed |
| US-4914093-A | CARDIOVASCULAR DISORDERS | SANKYO COMPANY LIMITED (JP) | 1990-04-03 | — | — | US | claimed |
| US-4812555-A | Peptides possessing renin inhibitory activity | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1989-03-14 | — | — | US | claimed |
| US-4755592-A | Statine-containing peptides useful in medicaments | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1988-07-05 | — | — | US | claimed |
| US-4436729-A | ANTIBIOTICS, BACTERICIDES | SCHERING CORPORATION (US) | 1984-03-13 | — | — | US | claimed |
| US-4435388-A | Tylosin 20-imino-20-deoxo-4\"-acyl derivatives, pharmaceutical compositions and method of use | SCHERING CORPORATION (US) | 1984-03-06 | — | — | US | claimed |
| US-4269773-A | CEPHALOSPORINS | SHIONOGI & CO., LTD. (JP) | 1981-05-26 | — | — | US | claimed |
| US-4267340-A | BACTERICIDES; SYNTHESIS OF PENICILLINS AND CEPHALOSPORINS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-05-12 | — | — | US | claimed |
| US-4009159-A | PENICILLINS | FUJISAWA PHARMACEUTICAL CO., LTD. (JA) | 1977-02-22 | — | — | US | claimed |
| US-3993646-A | Process for the ring expansion of penicillins to cephalosporin compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JA) | 1976-11-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062271-A1 | Antithrombotic Diamides | TFPI, SERPINC1, TFPI2 | CYP1A2 936/4885SIGMAR1 4478/4885HPGD 225/4885 |
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | TRPV4, TRPC4, TRPV1 | CYP1A2 3159/4885SIGMAR1 764/4885HPGD 1044/4885 |
| US-10787484-B2 | Compositions and methods for treating cardiovascular disease | PCSK9, PCSK7, PCSK6 | CYP1A2 3180/4885SIGMAR1 4878/4885HPGD 2382/4885 |
| US-20190177366-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE | PCSK9, PCSK7, PCSK6 | CYP1A2 3180/4885SIGMAR1 4878/4885HPGD 2382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.